HLA-C and neoplasm: T cell receptor fusion constructs (TRuCs) are comprised of an antibody-based binding domain (single-chain variable fragment, scFv) fused to one of the TCR subunits, which can recognize tumor surface antigens effectively via reprogramming TCR complex and kill tumor cells independent of MHC [11].